BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
BioAge Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.99+0.15 (+3.10%)
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
BioAge Labs, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -1026.3%
- Net margin
- -912.3%
- Return on equity, FY2025
- -27.1%
Financial strength
- Current ratio
- 17.19
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 384.9%
Valuation
- P/E ratio
- –
- Price to sales
- 21.61
- Price to book
- 0.60
- Dividend yield
- –